These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 11759381)
1. [The safety of new quinolone treatment--levoflaxacin (tavanic) and moxiflocacin (megaxin)-- in the community]. Bolkovshtein M; Lederman N; Berkovitch M Harefuah; 2001 Nov; 140(11):1054-7. PubMed ID: 11759381 [No Abstract] [Full Text] [Related]
2. An updated safety profile of moxifloxacin. Iannini PB; Mandell LA J Chemother; 2002 Feb; 14 Suppl 2():29-34. PubMed ID: 12003138 [No Abstract] [Full Text] [Related]
3. Recurrent tendinitis after treatment with two different fluoroquinolones. Burkhardt O; Köhnlein T; Pap T; Welte T Scand J Infect Dis; 2004; 36(4):315-6. PubMed ID: 15198194 [TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. Constantinou M; Daniell M; Snibson GR; Vu HT; Taylor HR Ophthalmology; 2007 Sep; 114(9):1622-9. PubMed ID: 17822972 [TBL] [Abstract][Full Text] [Related]
11. [Do tendon lesions occur during quinolone administration?]. Shah P Dtsch Med Wochenschr; 2003 Oct; 128(42):2214. PubMed ID: 14562223 [No Abstract] [Full Text] [Related]
12. Moxifloxacin: new preparation. A me-too with more cardiac risks. Prescrire Int; 2002 Dec; 11(62):168-9. PubMed ID: 12469694 [TBL] [Abstract][Full Text] [Related]
13. Systemic anaphylaxis caused by moxifloxacin. Sánchez-Morillas L; Rojas Pérez-Ezquerra P; Reaño-Martos M; Laguna-Martínez JJ; Gómez-Tembleque P Allergol Immunopathol (Madr); 2010; 38(4):226-7. PubMed ID: 20089346 [No Abstract] [Full Text] [Related]
14. [Effectiveness of a new fluoroquinolone antibiotic avelox in the treatment of suppurative sinusitis]. Egorov VI; Kozarenko AV Vestn Otorinolaringol; 2002; (5):35-6. PubMed ID: 12524963 [No Abstract] [Full Text] [Related]
15. Concurrent use of selected agents with moxifloxacin: an examination of labeling compliance within 1 year of marketing. Brinker A; Staffa J Arch Intern Med; 2002 Sep; 162(17):2011-2. PubMed ID: 12230426 [No Abstract] [Full Text] [Related]
16. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay. Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876 [TBL] [Abstract][Full Text] [Related]